Format

Send to

Choose Destination
See comment in PubMed Commons below
Leukemia. 2015 May;29(5):999-1003. doi: 10.1038/leu.2015.29. Epub 2015 Feb 5.

Laboratory recommendations for scoring deep molecular responses following treatment for chronic myeloid leukemia.

Author information

1
1] Faculty of Medicine, University of Southampton, Southampton, UK [2] National Genetics Reference Laboratory (Wessex), Salisbury District Hospital, Salisbury, UK.
2
Hematopathology Unit, Hospital Clinic, IDIBAPS, Barcelona, Spain.
3
Department of Clinical Genetics, Laboratory Medicine, Lund University, Lund, Sweden.
4
Imperial Molecular Pathology Laboratory, Centre for Haematology, Imperial College London, London, UK.
5
Department of Clinical and Biological Science, University of Turin, Turin, Italy.
6
Abteilung für Hämatologie und internistische Onkologie, Universität Leipzig, Leipzig, Germany.
7
Children's Cancer Research Institute/LabDia Labordiagnostik and Medical University, Vienna, Austria.
8
Institute of Hematology and Blood Transfusion, Prague, Czech Republic.
9
Laboratoire Hematologie, CHU Bordeaux, Hematopoiese Leucemique et Cibles Therapeutiques, INSERM U1035, Université Bordeaux, Bordeaux, France.
10
Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Bologna, Italy.
11
Molecular Diagnostics Laboratory, Department of Hematology, University Hospital Bern, Bern, Switzerland.
12
Klinisk Biokemi, Vejle Sygehus, Vejle, Denmark.
13
Department of Molecular Medicine and Surgery, Clinical Genetics, Karolinska Institutet, Stockholm, Sweden.
14
Hematology Department, Jagiellonian University, Krakow, Poland.
15
Hematology Department - Fundeni Clinical Institute, University of Medicine and Pharmacy 'Carol Davila', Bucharest, Romania.
16
Department of Clinical Medicine and Surgery, University 'Federico II' of Naples, Naples, Italy.
17
1] Department of Clinical Medicine and Surgery, University 'Federico II' of Naples, Naples, Italy [2] CEINGE - Biotecnologie Avanzate, Naples, Italy.
18
III. Medizinische Klinik, Universitätsmedizin Mannheim, Mannheim, Germany.
19
Abteilung Hämatologie/Onkologie, Klinik für Innere Medizin II, Universitätsklinikum Jena, Jena, Germany.

Abstract

Treatment of chronic myeloid leukemia (CML) with tyrosine kinase inhibitors has advanced to a stage where many patients achieve very low or undetectable levels of disease. Remarkably, some of these patients remain in sustained remission when treatment is withdrawn, suggesting that they may be at least operationally cured of their disease. Accurate definition of deep molecular responses (MRs) is therefore increasingly important for optimal patient management and comparison of independent data sets. We previously published proposals for broad standardized definitions of MR at different levels of sensitivity. Here we present detailed laboratory recommendations, developed as part of the European Treatment and Outcome Study for CML (EUTOS), to enable testing laboratories to score MR in a reproducible manner for CML patients expressing the most common BCR-ABL1 variants.

PMID:
25652737
PMCID:
PMC4430701
DOI:
10.1038/leu.2015.29
[Indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments

    Supplemental Content

    Full text links

    Icon for Nature Publishing Group Icon for PubMed Central
    Loading ...
    Support Center